DJIA 16,014.38 -12.67 -0.08%
NASDAQ 4,268.76 -14.99 -0.35%
S&P 500 1,852.21 -1.23 -0.07%
market minute promo

Gilead Sciences (NASDAQ: GILD)

87.25 1.99 (2.33%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $87.25 2.33%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $84.20
Previous Close $85.26
Daily Range $84.10 - $88.48
52-Week Range $81.89 - $123.37
Market Cap $125.7B
P/E Ratio 6.76
Dividend (Yield) $1.72 (2.0%)
Ex-Dividend Date
Dividend Pay Date
03/14/16
03/30/16
Volume 14,312,202
Average Daily Volume 13,396,908
Current FY EPS $12.00

Sector

Healthcare

Industry

Drug Makers

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary Rss Feed

3 Biotech Stocks to Buy in a Market Crash

Gilead Sciences, Celgene Corp, and Regeneron Pharmaceuticals are best-in-class in biotech.

Biotech ETFs Slide as Stocks Report Mixed Q4 Results

Icahn, Gilead, GE Lead Top Insider Trades Of The Week

The Agony of High Returns

Even with a time machine, a lot of people wouldn't want to own the best-performing stocks.

Gilead: I Want To Sell But I Can't

Gilead: Buyout Targets Abound

Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for February 10, 2016

Curing Hepatitis C: How Gilead Sciences Plans to Beat Merck

Merck's Zepatier poses a new challenge to Gilead's best-selling drug, but maybe it's not as threatening as some think.

Rebound For Big Biotech ETF Will Require Some Patience

Bristol-Myers' Daklinza-Sovaldi Label Expanded by the FDA

See More GILD News...

GILD's Top Competitors

GILD $87.25 (2.33%)
Current stock: GILD
AMGN $143.16 (0.11%)
Current stock: AMGN
CELG $100.50 (1.33%)
Current stock: CELG
$0.00 (0.00%)
Current stock: